Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SKELAXIN vs BACLOFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Skelaxin (metaxalone) is a centrally acting skeletal muscle relaxant. Its exact mechanism of action is not fully understood, but it is believed to act primarily by depressing the central nervous system (CNS) through inhibition of polysynaptic reflexes at the spinal and supraspinal levels, leading to muscle relaxation without directly affecting the neuromuscular junction or muscle fibers.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
FDA-approved: Adjunctive treatment for acute, painful musculoskeletal conditions (muscle spasms) associated with strains, sprains, and other muscle injuries.,Off-label: Chronic low back pain, fibromyalgia, tension headaches, cerebral palsy, multiple sclerosis (adjunctive).
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
800 mg orally three to four times daily.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
1-2 hours (terminal elimination half-life); clinical context: short duration of action, requires multiple daily dosing
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Metaxalone is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP1A2 and to a lesser extent CYP2D6, CYP2E1, and CYP3A4. It undergoes oxidative metabolism and glucuronidation. The major metabolites are hydroxylated derivatives and their glucuronide conjugates, which are inactive.
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Primarily renal (approximately 99% as unchanged drug); <1% fecal
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
75-80% bound, primarily to albumin
30-35% bound to albumin.
Vd/F ~ 1.5 L/kg; indicates extensive tissue distribution
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Oral: 25-30% (due to first-pass metabolism)
Oral: 70-85% with high variability; intrathecal: 100%.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to risk of accumulation.
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
Contraindicated in hepatic impairment; avoid use in Child-Pugh class A, B, or C.
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
Not recommended for pediatric patients due to lack of safety and efficacy data.
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
Initiate at lower doses (e.g., 400 mg three to four times daily) due to increased sensitivity and risk of adverse effects; monitor closely.
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
None
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
Central nervous system depression (sedation, dizziness, drowsiness); may impair ability to drive or operate machinery. Concomitant use with alcohol or other CNS depressants may enhance effects. Hepatotoxicity (rare but serious; monitor liver enzymes in patients with pre-existing liver disease). Serotonin syndrome risk when used with other serotonergic drugs. Risk of abuse and dependence (less than benzodiazepines, but caution in substance abuse history). Photosensitivity (avoid prolonged sun exposure).
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Absolute: Known hypersensitivity to metaxalone or any component; significantly impaired renal or hepatic function; history of drug-induced hemolytic anemia or other blood dyscrasias. Relative: Severe hepatic impairment; caution in patients with pre-existing liver disease, renal impairment, or older adults. Pregnancy (Category C; use only if benefit outweighs risk). Lactation (not recommended). Pediatric use (<12 years: safety not established).
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
Taking with food, especially high-fat meals, may increase absorption and risk of side effects. Avoid alcohol, as it increases CNS depression. No specific foods to avoid, but maintain consistent intake timing relative to meals.
No specific food interactions. Avoid alcohol due to additive CNS depression.
Risk summary: Not known to increase risk of major birth defects; limited human data. First trimester: No increased risk reported; animal studies show no teratogenicity. Second and third trimesters: No specific risks documented but should be used only if clearly needed. Fetal effects: Potential for muscle relaxation, but no clear adverse outcomes.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
Present in human milk; M/P ratio unknown. Limited data suggest no adverse effects in breastfed infants; caution advised. Use only if benefit outweighs risk.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
No dose adjustment recommended; pharmacokinetic changes in pregnancy not well studied. Use lowest effective dose for shortest duration.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
Skelaxin (metaxalone) is a centrally acting muscle relaxant indicated for acute musculoskeletal pain. Onset is about 1 hour with a duration of 4-6 hours. Drowsiness is the most common side effect; avoid concurrent use with alcohol or other CNS depressants. Not recommended in patients with significant hepatic impairment due to extensive hepatic metabolism. Tablets should be taken with food to reduce GI upset, but high-fat meals can increase Cmax and AUC.
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or hazardous activities until you know how you react.,Avoid alcohol while taking this medication.,Take with food or milk to prevent stomach upset.,Do not stop suddenly; follow doctor's instructions for discontinuation.,Report any signs of liver problems (yellowing skin/eyes, dark urine, persistent nausea) to your doctor immediately.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
No interactions on record
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SKELAXIN vs BACLOFEN, answered by our medical review team.
SKELAXIN is a Skeletal muscle relaxant that works by Skelaxin (metaxalone) is a centrally acting skeletal muscle relaxant. Its exact mechanism of action is not fully understood, but it is believed to act primarily by depressing the central nervous system (CNS) through inhibition of polysynaptic reflexes at the spinal and supraspinal levels, leading to muscle relaxation without directly affecting the neuromuscular junction or muscle fibers.. BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SKELAXIN and BACLOFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SKELAXIN is: 800 mg orally three to four times daily.. The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SKELAXIN and BACLOFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SKELAXIN is classified as Category C. Risk summary: Not known to increase risk of major birth defects; limited human data. First trimester: No increased risk reported; animal studies show no teratogenicity. Second and . BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.